Young L S
Am J Med. 1981 Feb;70(2):398-404. doi: 10.1016/0002-9343(81)90779-8.
It is universally accepted that the immunocompromised host is more susceptible to nosocomial infection than the normal host. Descriptive clinical or epidemiologic studies that utilize the "organism oriented" approach are now abundant. Generalizations about risk factors are difficult to make, however, because of the wide range of host defects that are usually compounded by therapeutic intervention. Comparative data are lacking on whether certain procedures or treatments are associated with a higher incidence of infection in immunocompromised hosts versus normal hosts. Aggressive diagnostic and therapeutic approaches to nosocomial infection in immunocompromised patients are usually advocated, but there have been few prospective studies of their effectiveness and the possible increased hazard of nosocomial infection. The paramount questions that must be addressed are, "What infections are preventable and how?" Two derivative issues relate to (1) the cost to benefit aspects of preventive measures, and (2) the impact of such measures on survival from underlying disease. Rigorously controlled studies of specific preventative measures are clearly required because the appearance of improvement may be related to concurrent improvements in the treatment of underlying disease or its complications. The ultimate value of infection control programs in immunocompromised patients with depend on the demonstration that intervention not only reduces infection rates but also has a favorable impact on the treatment of the underlying disease.
普遍认为,免疫功能低下的宿主比正常宿主更容易发生医院感染。目前,采用“以病原体为导向”方法的描述性临床或流行病学研究大量涌现。然而,由于宿主缺陷范围广泛,且通常因治疗干预而更加复杂,因此很难对危险因素进行归纳总结。目前缺乏关于某些操作或治疗在免疫功能低下宿主与正常宿主中是否会导致更高感染发生率的比较数据。通常提倡对免疫功能低下患者的医院感染采取积极的诊断和治疗方法,但很少有前瞻性研究探讨其有效性以及医院感染可能增加的风险。必须解决的首要问题是:“哪些感染是可以预防的?如何预防?”两个衍生问题涉及:(1)预防措施的成本效益方面;(2)这些措施对基础疾病生存率的影响。显然需要对特定预防措施进行严格对照研究,因为病情改善可能与基础疾病或其并发症治疗的同时改善有关。免疫功能低下患者感染控制项目的最终价值取决于能否证明干预措施不仅能降低感染率,而且对基础疾病的治疗有积极影响。